Sepracor&#39;s Dream Drug?
65963
Sepracor (Nasdaq: SEPR) scored a major victory yesterday, though investors should have their eyes wide open when considering the stock.
294794
Scrutiny of other pain relievers urged over fear they, too, may lead to heart problems. By Marilynn Marchione. Momentum was growing for a fresh look at the safety of Celebrex and other pain relievers as key
686027
Sepracor Inc. won a long-awaited approval to sell its new prescription sleep aid, a drug that may help push the money-losing company to a profit.
87010
New data are due out on a promising cholesterol drug. But there are doubters.
33718
Will the drugmaker's hefty R&D bill pay off?
506148
It's running trials to see if the drug can be used in earlier stages of cancer.
136421
Millions of Americans have done just that. Thanks to them, a class of pain relievers called COX-2 inhibitors - Pfizer&#39;s Celebrex and Bextra, and Merck&#39;s Vioxx - have become blockbusters.
502607
Doctors are hopeful about a new drug to treat skin cancer by causing tumor cells to self-destruct by overloading them with oxygen
664968
Promising drug test results make this a company to watch.
589264
Panacos releases more clinical trial results for an exciting drug.
171695
What you hear before taking prescription drugs versus what you learn afterward may make you feel like a lab rat. Before: Bayer&#39;s Baycol lowers cholesterol.
358115
Tekturna, the first new type of blood pressure medicine in more than a decade, is a potential blockbuster for the Swiss pharmaceutical maker Novartis.
664016
âWe show, for the first time, we can deliver these potentially high-quality therapeutics to an animal.â Hans-Peter Vornlocher, Scientist, Alnylam Pharmaceuticals.
232912
It would seem a drug executive&#39;s dream come true. A week ago Thursday, the secretary of health and human services summoned the top officials of MedImmune to his office in Washington to ask
764344
The anti-industry crusader targets pharmaceuticals.
714241
Synta Pharmaceuticals Corp. knows a thing or two about developing drugs. It has pretty impressive skills when it comes to money, too.
528592
Sepracor Inc  posted lower third-quarter earnings on Tuesday, hurt by a decline in sales of its respiratory drug Xopenex, but the company's shares rose 14 percent in premarket trading after it said it would cut about 300 positions from its sales force.